Table 4.

Number of patients experiencing overall grade 3-5 toxicities in each study.

Study	Experimental group		Control group
	No. of grade 3-4	Total patients	No. of grade 3-4	Total patients
Brahmer 2015	9 (6.8%)	131	71 (55.0%)	129
Borghaei 2015	30 (10.5%)	287	144 (53.7%)	268
Herbst 2015 (arm 1)a	43 (12.7%)	339	109 (35.3%)	309
Herbst 2015 (arm 2)a	55 (16.0%)	343	109 (35.3%)	309
Fehrenbacher 2016	16 (11.3%)	142	52 (38.5%)	135
Rittmeyer 2017	90 (14.8%)	609	248 (42.9%)	578

^a Arm 1: pembrolizumab 2 mg/kg; Arm 2: pembrolizumab 10mg/kg.